Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Neutral

Analyst Rating

Strong Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Buy

Insider Trading

Buy

Wall Street Data Solutions Rating

Strong Buy

S

Halozyme Therapeutics, Inc. (HALO)

Biological Products, (no Disgnostic Substances)

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

12390 EL CAMINO REAL
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

03/12/2004

Market Cap

7,607,013,900

Shares Outstanding

132,100,000

Weighted SO

132,098,110

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

AGIO --.--%

INSM --.--%

CERE --.--%

RARE --.--%

BMRN --.--%

SGEN --.--%

ALNY --.--%

EXEL --.--%

ALEC --.--%

Beta

1.2710

Last Div

0.0000

Range

32.83-60.15

Chg

0.9500

Avg Vol

1326470

Mkt Cap

7607013900

Exch

NASDAQ

Country

US

Phone

858 794 8889

DCF Diff

41.3607

DCF

18.4793

Div Yield

0.0000

P/S

8.7106

EV Multiple

18.5083

P/FV

26.3742

Div Yield %

0.0000

P/E

22.6311

PEG

7.6255

Payout

0.0400

Current Ratio

7.4070

Quick Ratio

6.2124

Cash Ratio

1.4087

DSO

89.6609

DIO

276.1341

Op Cycle

365.7951

DPO

26.7447

CCC

339.0504

Gross Margin

0.7589

Op Margin

0.4604

Pretax Margin

0.4772

Net Margin

0.3862

Eff Tax Rate

0.1906

ROA

0.1713

ROE

1.6860

ROCE

0.2190

NI/EBT

0.8094

EBT/EBIT

1.0363

EBIT/Rev

0.4604

Debt Ratio

0.7785

D/E

5.2973

LT Debt/Cap

0.8385

Total Debt/Cap

0.8412

Int Coverage

41.4185

CF/Debt

0.2739

Equity Multi

6.8047

Rec Turnover

4.0709

Pay Turnover

13.6476

Inv Turnover

1.3218

FA Turnover

11.6441

Asset Turnover

0.4434

OCF/Share

3.3040

FCF/Share

3.2122

Cash/Share

4.1618

OCF/Sales

0.4809

FCF/OCF

0.9722

CF Coverage

0.2739

ST Coverage

13.6964

CapEx Coverage

35.9978

Div&CapEx Cov

16.6992

P/BV

26.3742

P/B

26.3742

P/S

8.7106

P/E

22.6311

P/FCF

18.6301

P/OCF

18.1752

P/CF

18.1752

PEG

7.6255

P/S

8.7106

EV Multiple

18.5083

P/FV

26.3742

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Apr 10, 21:47 argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Benzinga Jan 18, 13:28 Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion Benzinga Jan 18, 12:00 Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts The Motley Fool Jan 16, 10:30 4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond Benzinga Dec 26, 11:00 Expert Outlook: Halozyme Therapeutics Through The Eyes Of 4 Analysts

Revenue Product Segmentation